 The Netherlands Grants AIM a Patent for Ampligen as a Cancer Therapy for Use in Combination with Checkpoint Blockade Inhibitors The Netherlands Grants AIM a Patent for Ampligen as a Cancer Therapy for Use in Combination with Checkpoint Blockade Inhibitors 